Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.08
MYL's Cash to Debt is ranked lower than
91% of the 779 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.56 vs. MYL: 0.08 )
Ranked among companies with meaningful Cash to Debt only.
MYL' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.77 Max: N/A
Current: 0.08
Equity to Asset 0.32
MYL's Equity to Asset is ranked lower than
87% of the 718 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. MYL: 0.32 )
Ranked among companies with meaningful Equity to Asset only.
MYL' s Equity to Asset Range Over the Past 10 Years
Min: 0.19  Med: 0.44 Max: 0.9
Current: 0.32
0.19
0.9
Interest Coverage 2.15
MYL's Interest Coverage is ranked lower than
90% of the 622 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 101.94 vs. MYL: 2.15 )
Ranked among companies with meaningful Interest Coverage only.
MYL' s Interest Coverage Range Over the Past 10 Years
Min: 0.83  Med: 3.61 Max: 9.19
Current: 2.15
0.83
9.19
F-Score: 3
Z-Score: 0.92
M-Score: -2.65
WACC vs ROIC
10.18%
4.07%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 7.86
MYL's Operating margin (%) is ranked lower than
52% of the 731 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.61 vs. MYL: 7.86 )
Ranked among companies with meaningful Operating margin (%) only.
MYL' s Operating margin (%) Range Over the Past 10 Years
Min: 5.8  Med: 16.36 Max: 26.53
Current: 7.86
5.8
26.53
Net-margin (%) 2.50
MYL's Net-margin (%) is ranked lower than
64% of the 732 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.89 vs. MYL: 2.50 )
Ranked among companies with meaningful Net-margin (%) only.
MYL' s Net-margin (%) Range Over the Past 10 Years
Min: -3.53  Med: 9.01 Max: 14.68
Current: 2.5
-3.53
14.68
ROE (%) 2.47
MYL's ROE (%) is ranked lower than
65% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.84 vs. MYL: 2.47 )
Ranked among companies with meaningful ROE (%) only.
MYL' s ROE (%) Range Over the Past 10 Years
Min: -14.72  Med: 14.57 Max: 29.99
Current: 2.47
-14.72
29.99
ROA (%) 0.98
MYL's ROA (%) is ranked lower than
64% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. MYL: 0.98 )
Ranked among companies with meaningful ROA (%) only.
MYL' s ROA (%) Range Over the Past 10 Years
Min: -2.47  Med: 4.61 Max: 9.21
Current: 0.98
-2.47
9.21
ROC (Joel Greenblatt) (%) 11.06
MYL's ROC (Joel Greenblatt) (%) is ranked lower than
55% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.31 vs. MYL: 11.06 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MYL' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 11.06  Med: 31.19 Max: 47.2
Current: 11.06
11.06
47.2
Revenue Growth (3Y)(%) 5.40
MYL's Revenue Growth (3Y)(%) is ranked higher than
50% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.50 vs. MYL: 5.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MYL' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -6.1  Med: 15.2 Max: 54.5
Current: 5.4
-6.1
54.5
EBITDA Growth (3Y)(%) 5.20
MYL's EBITDA Growth (3Y)(%) is ranked lower than
58% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.40 vs. MYL: 5.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MYL' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -20.4  Med: 11.2 Max: 107.9
Current: 5.2
-20.4
107.9
EPS Growth (3Y)(%) 3.80
MYL's EPS Growth (3Y)(%) is ranked lower than
58% of the 531 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. MYL: 3.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MYL' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -29.1  Med: 3.8 Max: 110.4
Current: 3.8
-29.1
110.4
GuruFocus has detected 4 Warning Signs with Mylan NV $MYL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MYL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

MYL Guru Trades in Q4 2015

Joel Greenblatt 9,029 sh (New)
David Einhorn 2,890,000 sh (New)
David Tepper 853,749 sh (+81.62%)
Pioneer Investments 469,785 sh (+28.60%)
Vanguard Health Care Fund 24,253,075 sh (+4.26%)
John Paulson 22,794,061 sh (+4.02%)
Tom Russo 5,850 sh (unchged)
Steven Cohen 1,000,000 sh (unchged)
Samuel Isaly 548,000 sh (unchged)
Larry Robbins Sold Out
Kyle Bass Sold Out
Jim Simons Sold Out
Keeley Asset Management Corp 51,580 sh (-8.09%)
Paul Tudor Jones 8,100 sh (-24.78%)
Louis Moore Bacon 38,678 sh (-51.65%)
Mario Gabelli 26,450 sh (-60.67%)
Scott Black 48,980 sh (-72.88%)
Steven Cohen 100 sh (-99.97%)
» More
Q1 2016

MYL Guru Trades in Q1 2016

Joel Greenblatt 837,728 sh (+9178.19%)
Vanguard Health Care Fund 26,679,385 sh (+10.00%)
John Paulson 23,335,861 sh (+2.38%)
David Einhorn 2,890,000 sh (unchged)
John Paulson 611,200 sh (unchged)
Steven Cohen Sold Out
Keeley Asset Management Corp Sold Out
Louis Moore Bacon Sold Out
David Tepper Sold Out
Samuel Isaly Sold Out
Tom Russo 5,395 sh (-7.78%)
Scott Black 42,509 sh (-13.21%)
Paul Tudor Jones 6,455 sh (-20.31%)
Mario Gabelli 17,000 sh (-35.73%)
Pioneer Investments 54,144 sh (-88.47%)
» More
Q2 2016

MYL Guru Trades in Q2 2016

Lee Ainslie 2,294,698 sh (New)
David Einhorn 4,945,000 sh (+71.11%)
Paul Tudor Jones 9,355 sh (+44.93%)
Vanguard Health Care Fund 27,965,385 sh (+4.82%)
Pioneer Investments 54,144 sh (unchged)
Paul Tudor Jones 80,000 sh (unchged)
John Paulson 1,030,400 sh (unchged)
Tom Russo Sold Out
Joel Greenblatt Sold Out
Scott Black 41,144 sh (-3.21%)
John Paulson 22,028,061 sh (-5.60%)
Mario Gabelli 14,000 sh (-17.65%)
» More
Q3 2016

MYL Guru Trades in Q3 2016

Joel Greenblatt 21,460 sh (New)
David Einhorn 6,400,000 sh (+29.42%)
Paul Tudor Jones 10,900 sh (+16.52%)
Mario Gabelli 16,012 sh (+14.37%)
Vanguard Health Care Fund 29,148,837 sh (+4.23%)
Pioneer Investments 54,839 sh (+1.28%)
Scott Black 41,176 sh (+0.08%)
John Paulson 940,400 sh (unchged)
John Paulson 21,811,661 sh (-0.98%)
Lee Ainslie 1,336,436 sh (-41.76%)
» More
» Details

Insider Trades

Latest Guru Trades with MYL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:OTCPK:ESALY, OTCPK:SGIOY, OTCPK:MKGAY, NYSE:ZTS, OTCPK:MTZPY, NYSE:PRGO, OTCPK:APNHY, OTCPK:HLUYY, OTCPK:SFOSF, OTCPK:TKPYY, NYSE:RDY, OTCPK:IPSEY, NYSE:TEVA, OTCPK:HKMPF, OTCPK:HYPMY, NYSE:VRX, NYSE:MNK, NAS:OPK, NYSE:TARO, NYSE:PTHN » details
Traded in other countries:6MY.Germany, MYL1.Switzerland, 0R5P.UK,
Mylan NV together with its subsidiaries, is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals.

Mylan NV was incorporated in Netherlands on July 7, 2014. The Company along with its subsidiaries is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. It also operates a research and development network that delivers a robust product pipeline. The Company operates in two segments, Generics and Specialty. The Generics segment develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as active pharmaceutical ingredients. The generic pharmaceutical business is conducted in the U.S. and Canada, Europe, the Middle East, and Africa and India, Australia, Japan, New Zealand and Brazil. The Specialty segment engages in the development and sale of branded specialty nebulized and injectable products. The Company owns or licenses a number of patents in the U.S. and other countries covering certain products and has also developed brand names and trademarks for other products. In North America, the Company markets products directly to wholesalers, distributors, retail pharmacy chains, long-term care facilities, mail order pharmacies and GPOs. It also market its generic products indirectly to independent pharmacies, managed care organizations, hospitals, nursing homes, pharmacy benefit management companies and government entities. The Company's competitors include other generic companies and branded drug companies that continue to sell or license branded pharmaceutical products after patent expirations and other statutory expirations. In the branded space, key competitors are generally other branded drug companies that compete based on its clinical characteristics and benefits.

Guru Investment Theses on Mylan NV

John Keeley Comments on Mylan Labs - Apr 26, 2016

Mylan Labs (NASDAQ:MYL), another detractor, announced a slightly weaker quarter than expected as well as the acquisition of European-based Meda, which appeared expensive in our opinion. We met with management at a recent investor conference and discussed their failed hostile takeover attempt of Perrigo (PRGO), their rebuffing of Teva Pharmaceutical’s simultaneous acquisition offer, and its acquisition of Meda. Even though we believe the stock is relatively cheap, we did not receive satisfactory responses to our questions; as such we elected to sell the position.



From Keeley All Cap Value Fund first quarter 2016 commentary.



Check out John Keeley latest stock trades

Keeley Funds Comments on Mylan N.V. - Feb 03, 2016

The Fund’s largest contributor during the quarter was Mylan N.V (NASDAQ:MYL) which rose over 34 percent and added 84 basis points of return to the Fund. Shares were initially weak following its failed bid to merge with rival Perrigo (NYSE:PRGO). We viewed the failed bid as a positive as we were skeptical of the synergies between the two companies. We increased our exposure to the stock during the weakness as we believe the shares are very cheap on a valuation basis.



From the Keeley All Cap Value Fund 4th quarter 2015 shareholder letter.



Check out John Keeley latest stock trades

David Einhorn Comments on Mylan - Jan 19, 2016

We initiated a position in Mylan (NASDAQ:MYL), a global generic pharmaceuticals company. MYLshares fell 29% in the first three quarters of 2015 and over 45% from their mid-year highsafter generics rival Teva abandoned a hostile takeover bid for the company. During the fall,the market became overly focused on a series of overhangs including potential earningsdilution from a proposed and ultimately failed buyout of Perrigo (a private-label OTC business); corporate governance concerns including an unusual takeover-defense mechanism;and widespread unease about the pharmaceutical sector amidst scrutiny of specialty pharmaceutical manufacturers like Valeant.

We acknowledge eventual headwinds for the company’s branded EpiPen product, whichcould encounter competition from generics in late 2016. However, we see medium-termupside from a competitor recall, an announced share repurchase, and board review ofcorporate governance complaints. Ultimately, we expect MYL to earn close to $7 per share in2018, driven by a robust pipeline of respiratory, injectable and biologic drugs and by furthercapital deployment including share repurchases. We initiated our position at an average priceof $45.32, about 9x 2016 consensus EPS estimates. MYL shares ended the quarter at $54.07.

From David Einhorn (Trades, Portfolio)'s Green Light Capital fourth quarter 2015 shareholder letter.

Check out David Einhorn latest stock trades

Keeley Funds Comments on Mylan NV - Nov 03, 2015

The largest detractor during the quarter was in the health care sector after Mylan NV (NASDAQ:MYL) fell over 40 percent and cost the Fund 83 basis points in performance. The key development that pressured the stock was when rival TEVA Pharmaceutical (NYSE:TEVA) removed its takeover bid and instead acquired Allergan PLC’s (NYSE:AGN) generic business. Mylan remains interested in acquiring Perrigo (NYSE:PRGO) who prefers to remain independent. In addition, all of healthcare, and drug makers specifically, are seeing considerable selling pressure due to Valiant Pharmaceutical’s (NYSE:VRX) specialty pharmacy sales and Mylan does not use specialty pharmacies. Lastly, political rhetoric about price controls in health care is being bandied about by the Democratic frontrunner and those comments have had a negative impact on the entire industry.





From the Keeley All-Cap Value Fund commentary on third quarter 2015.



Check out John Keeley latest stock trades

Vanguard Health Care Fund Comments on Mylan NV - Mar 27, 2015

We increased our position in this global generic pharmaceutical manufacturer as its core generic business remains steady and has benefited from selective price increases. We believe the planned acquisition of Abbott’s non-U.S. established pharmaceuticals business will augment the company’s globalization strategy.

From Vanguard Health Care Fund (Trades, Portfolio) 2014 Annual Report

Check out Vanguard Health Care Fund latest stock trades

Top Ranked Articles about Mylan NV

Mylan Posts Loss Amid Investigation, Settlement Pharmaceutical company joins Valeant in reporting a loss
Mylan (NASDAQ:MYL) released its third-quarter earnings Wednesday, reporting a quarterly loss and revenue growth that was below expectations. Read more...
David Einhorn Speaks on Passive Investing, Mylan, His Cheapest Stock, the Fed GuruFocus covered Einhorn at Great Investors' Best Ideas conference
Greenlight Capital hedge fund manager David Einhorn (Trades, Portfolio) joined nine other famed investors on Tuesday to talk about stocks at the annual Great Investors’ Best Ideas Investment Symposium in Dallas. Read more...
Samuel Isaly Trades in Health Care Stocks in 1st Quarter Guru sells stakes in Health Net, Mylan, trims stake in Bristol-Myers Squibb
Samuel Isaly (Trades, Portfolio), manager of Eaton Vance Worldwide Health Sciences Fund, was an active investor in health care-related stocks long before government became involved in the sector. His transactions in the first quarter, ended Feb. 29, reflected that interest. Read more...
John Keeley Comments on Mylan Labs Guru stock highlight
Mylan Labs (NASDAQ:MYL), another detractor, announced a slightly weaker quarter than expected as well as the acquisition of European-based Meda, which appeared expensive in our opinion. We met with management at a recent investor conference and discussed their failed hostile takeover attempt of Perrigo (PRGO), their rebuffing of Teva Pharmaceutical’s simultaneous acquisition offer, and its acquisition of Meda. Even though we believe the stock is relatively cheap, we did not receive satisfactory responses to our questions; as such we elected to sell the position. Read more...
Keeley Funds Comments on Mylan N.V. Guru stock highlight
The Fund’s largest contributor during the quarter was Mylan N.V (NASDAQ:MYL) which rose over 34 percent and added 84 basis points of return to the Fund. Shares were initially weak following its failed bid to merge with rival Perrigo (NYSE:PRGO). We viewed the failed bid as a positive as we were skeptical of the synergies between the two companies. We increased our exposure to the stock during the weakness as we believe the shares are very cheap on a valuation basis. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 72.16
MYL's P/E(ttm) is ranked lower than
84% of the 531 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.62 vs. MYL: 72.16 )
Ranked among companies with meaningful P/E(ttm) only.
MYL' s P/E(ttm) Range Over the Past 10 Years
Min: 7.32  Med: 25.42 Max: 112.56
Current: 72.16
7.32
112.56
Forward P/E 6.88
MYL's Forward P/E is ranked higher than
90% of the 67 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.95 vs. MYL: 6.88 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 72.16
MYL's PE(NRI) is ranked lower than
84% of the 532 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.66 vs. MYL: 72.16 )
Ranked among companies with meaningful PE(NRI) only.
MYL' s PE(NRI) Range Over the Past 10 Years
Min: 7.32  Med: 25.42 Max: 112.56
Current: 72.16
7.32
112.56
Price/Owner Earnings (ttm) 85.58
MYL's Price/Owner Earnings (ttm) is ranked lower than
82% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.46 vs. MYL: 85.58 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
MYL' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 13.15  Med: 34.77 Max: 122.57
Current: 85.58
13.15
122.57
P/B 1.66
MYL's P/B is ranked higher than
72% of the 750 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. MYL: 1.66 )
Ranked among companies with meaningful P/B only.
MYL' s P/B Range Over the Past 10 Years
Min: 0.64  Med: 2.6 Max: 7.02
Current: 1.66
0.64
7.02
P/S 1.82
MYL's P/S is ranked higher than
65% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.91 vs. MYL: 1.82 )
Ranked among companies with meaningful P/S only.
MYL' s P/S Range Over the Past 10 Years
Min: 0.41  Med: 1.81 Max: 4.71
Current: 1.82
0.41
4.71
PFCF 11.32
MYL's PFCF is ranked higher than
79% of the 200 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.43 vs. MYL: 11.32 )
Ranked among companies with meaningful PFCF only.
MYL' s PFCF Range Over the Past 10 Years
Min: 8.82  Med: 19.76 Max: 119.2
Current: 11.32
8.82
119.2
POCF 8.03
MYL's POCF is ranked higher than
81% of the 267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.46 vs. MYL: 8.03 )
Ranked among companies with meaningful POCF only.
MYL' s POCF Range Over the Past 10 Years
Min: 6.13  Med: 12.04 Max: 40.9
Current: 8.03
6.13
40.9
EV-to-EBIT 69.35
MYL's EV-to-EBIT is ranked lower than
89% of the 536 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.56 vs. MYL: 69.35 )
Ranked among companies with meaningful EV-to-EBIT only.
MYL' s EV-to-EBIT Range Over the Past 10 Years
Min: -10.3  Med: 18.05 Max: 74.5
Current: 69.35
-10.3
74.5
EV-to-EBITDA 18.13
MYL's EV-to-EBITDA is ranked lower than
53% of the 561 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.22 vs. MYL: 18.13 )
Ranked among companies with meaningful EV-to-EBITDA only.
MYL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -17.7  Med: 11 Max: 23.3
Current: 18.13
-17.7
23.3
PEG 9.60
MYL's PEG is ranked lower than
87% of the 281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.91 vs. MYL: 9.60 )
Ranked among companies with meaningful PEG only.
MYL' s PEG Range Over the Past 10 Years
Min: 0.74  Med: 2.77 Max: 13.32
Current: 9.6
0.74
13.32
Shiller P/E 83.41
MYL's Shiller P/E is ranked lower than
75% of the 159 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 44.99 vs. MYL: 83.41 )
Ranked among companies with meaningful Shiller P/E only.
MYL' s Shiller P/E Range Over the Past 10 Years
Min: 14.48  Med: 82.28 Max: 173.66
Current: 83.41
14.48
173.66
Current Ratio 0.83
MYL's Current Ratio is ranked lower than
91% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.34 vs. MYL: 0.83 )
Ranked among companies with meaningful Current Ratio only.
MYL' s Current Ratio Range Over the Past 10 Years
Min: 0.83  Med: 3.08 Max: 8.49
Current: 0.83
0.83
8.49
Quick Ratio 0.55
MYL's Quick Ratio is ranked lower than
93% of the 769 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.76 vs. MYL: 0.55 )
Ranked among companies with meaningful Quick Ratio only.
MYL' s Quick Ratio Range Over the Past 10 Years
Min: 0.55  Med: 2.52 Max: 6.76
Current: 0.55
0.55
6.76
Days Inventory 135.66
MYL's Days Inventory is ranked lower than
59% of the 680 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.19 vs. MYL: 135.66 )
Ranked among companies with meaningful Days Inventory only.
MYL' s Days Inventory Range Over the Past 10 Years
Min: 88.95  Med: 136.05 Max: 168.24
Current: 135.66
88.95
168.24
Days Sales Outstanding 109.82
MYL's Days Sales Outstanding is ranked lower than
75% of the 622 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.25 vs. MYL: 109.82 )
Ranked among companies with meaningful Days Sales Outstanding only.
MYL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 70.32  Med: 84.21 Max: 109.82
Current: 109.82
70.32
109.82
Days Payable 77.96
MYL's Days Payable is ranked higher than
56% of the 569 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 71.85 vs. MYL: 77.96 )
Ranked among companies with meaningful Days Payable only.
MYL' s Days Payable Range Over the Past 10 Years
Min: 44.56  Med: 72.5 Max: 101.21
Current: 77.96
44.56
101.21

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -7.50
MYL's 3-Year Average Share Buyback Ratio is ranked lower than
60% of the 429 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.40 vs. MYL: -7.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MYL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.5  Med: -0.8 Max: 8.6
Current: -7.5
-25.5
8.6

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.11
MYL's Price/Projected FCF is ranked higher than
82% of the 314 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.69 vs. MYL: 1.11 )
Ranked among companies with meaningful Price/Projected FCF only.
MYL' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.62  Med: 1.44 Max: 2.69
Current: 1.11
0.62
2.69
Price/DCF (Earnings Based) 6.79
MYL's Price/DCF (Earnings Based) is ranked lower than
97% of the 77 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.32 vs. MYL: 6.79 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.02
MYL's Price/Median PS Value is ranked higher than
61% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. MYL: 1.02 )
Ranked among companies with meaningful Price/Median PS Value only.
MYL' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.36  Med: 1.8 Max: 3.5
Current: 1.02
0.36
3.5
Price/Peter Lynch Fair Value 11.73
MYL's Price/Peter Lynch Fair Value is ranked lower than
97% of the 150 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.63 vs. MYL: 11.73 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
MYL' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.67  Med: 1.98 Max: 12.06
Current: 11.73
0.67
12.06
Earnings Yield (Greenblatt) (%) 1.41
MYL's Earnings Yield (Greenblatt) (%) is ranked lower than
63% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. MYL: 1.41 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MYL' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.3  Med: 5.3 Max: 19
Current: 1.41
1.3
19
Forward Rate of Return (Yacktman) (%) 11.11
MYL's Forward Rate of Return (Yacktman) (%) is ranked higher than
54% of the 344 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.63 vs. MYL: 11.11 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MYL' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 7.7  Med: 13.8 Max: 24.9
Current: 11.11
7.7
24.9

More Statistics

Revenue (TTM) (Mil) $10,300
EPS (TTM) $ 0.51
Beta1.45
Short Percentage of Float4.85%
52-Week Range $33.60 - 54.23
Shares Outstanding (Mil)535.11

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 11,001 12,811 13,126 13,643
EPS ($) 4.71 5.35 5.66 5.84
EPS w/o NRI ($) 4.71 5.35 5.66 5.84
EPS Growth Rate
(3Y to 5Y Estimate)
7.13%
Dividends Per Share ($)
» More Articles for MYL

Headlines

Articles On GuruFocus.com
Teva: Good Value, Questionable Management? Jan 02 2017 
Integer Investments: Akorn Has 100% Upside Potential Jan 01 2017 
Weak Outlook on Mylan Nov 18 2016 
3 Health Industry Sectors Bound to Profit From a Trump Presidency Nov 11 2016 
Mylan Posts Loss Amid Investigation, Settlement Nov 10 2016 
Buy Health Care Now? It All Depends on the Election Nov 07 2016 
Allergan: Trading at a Low Earnings Multiple Nov 06 2016 
David Einhorn Converses on Range of Topics, Stocks With New York Times Editor Oct 20 2016 
The Pharmaceutical Sector Looks Attractive Oct 12 2016 
John Paulson’s Health Care Picks Plunge in Flat Year for Sector Oct 06 2016 

More From Other Websites
EpiPen rival to be offered free to many but high price for insurers Jan 19 2017
U.S. health agency tells Grassley there is no EpiPen deal yet Jan 19 2017
[$$] Rival to EpiPen Allergy Treatment to Return to Market Jan 19 2017
U.S. health agency tells Grassley there is no EpiPen settlement yet Jan 19 2017
EpiPen Competitor Auvi-Q Will Return in February, but It'll Cost Insurance Companies Big Bucks Jan 19 2017
Kaleo Inc. says its competitor to Mylan's EpiPen will be available for $360 starting Feb. 14 Jan 19 2017
ETFs with exposure to Mylan NV : January 17, 2017 Jan 17 2017
CVS takes on Mylan’s EpiPen with much cheaper version of an alternative Jan 15 2017
Examining Volkswagen and Fiat Chrysler's Emissions Cheating Scandals Jan 13 2017
Fifth Street Asset Management, Cray, CVS Health, Mylan and Impax Laboratories highlighted as Zacks... Jan 13 2017
Mylan’s Recent Commercial and Product Developments Jan 13 2017
Mylan NV breached its 50 day moving average in a Bearish Manner : MYL-US : January 13, 2017 Jan 13 2017
Blog Coverage Expensive EpiPen Proves Costly for Mylan as Cigna Drops it from Coverage List; Opts... Jan 13 2017
Mylan’s Profit Margins: What Made Them Change? Jan 13 2017
Pharma Stock Roundup: Trump Targets Pharma Again, Merck Up on Keytruda News Jan 13 2017
Business Watch Jan 13 2017
UPDATE 1-CVS slashes price of Impax's EpiPen rival Jan 12 2017
CVS slashes price of Impax's emergency allergy shot Jan 12 2017
Mylan Crushed by Trump, Cigna and CVS -- All In Two Days Jan 12 2017
[$$] Cigna Drops EpiPen Coverage for Generic Jan 12 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)